TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to ...
- Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ ...
In a development few would have predicted just a few years ago, the Trump administration has voiced support for the ...
In the fast-evolving landscape of biotechnology, one company is making waves in the mental health treatment space with its innovative ...
Small Cap Bulls is your trusted source for uncovering small-cap companies on the brink of explosive growth. With in-depth analysis and expert insights, we help investors navigate the dynamic world of small-cap stocks. Join us as we charge ahead, empowering your investment journey.
2024 Small Cap Bulls – Charging Ahead. All Rights Reserved.
By using this site you agree to the Terms of Use, Privacy Policy, and Service Agreement.
Join our newsletter
